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Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and 47 
Huntington’s disease (HD) severely impact the function of neuronal cells in the brain and have 48 
devastating consequences on the quality of life of patients and their families [1–3]. In their 2018 49 
review, Hussain et al. presented common mechanistic pathologies that contribute to the 50 
neurodegenerative processes in these conditions as well as discussed novel therapeutic approaches 51 
aimed at targeting these aberrant signaling cascades [4]. Presently, the development of new treatment 52 
strategies for AD, PD and HD remain at the pre-clinical and clinical stages while commercially 53 
available and approved drugs predominantly alleviate symptoms temporarily without significantly 54 
altering disease progression [5–7]. Notably, the most commonly prescribed treatments for AD 55 
(memantine) and PD (levodopa) were approved by the U.S. Food and Drug Administration (FDA) in 56 
the early 2000s and 1970s [5,8], respectively, and no new life-changing disease-modifying drugs have 57 
reached patients since. The first regulated treatment for HD appeared in the late 2000s (tetrabenazine) 58 
and remained the sole option until a chemically modified version of the drug (deutetrabenazine) was 59 
recently approved by the FDA. Thus, despite herculean efforts from scientists, clinicians and 60 
pharmacological companies, we remain in a state of urgent need for groundbreaking therapies for 61 
neurodegenerative diseases.  62 
 63 
In their review, Hussain et al. provided evidence for the therapeutic potential of strategies aimed at 64 
modulating aberrantly regulated processes and pathways in AD, HD and PD such as protein 65 
aggregation, protein misfolding, inflammation, autophagy, glymphatic clearance, neurogenesis, 66 
glucose metabolism and the cholinergic system [4]. There have since been some exciting and positive 67 
achievements.  68 
 69 
Indeed, at the beginning of 2020, Aducanumab (BIIB037), the monoclonal antibody developed by 70 
Biogen to reduce disease-specific protein aggregates in AD, has entered a Phase 3b open-label clinical 71 
trial with 2400 patients (ClinicalTrials.gov Identifier: NCT04241068) [9]. While the safety and 72 
tolerability outcomes are only expected in late 2023, Biogen has nevertheless submitted a biological 73 
license application with priority review for Aducanumab.   74 
 75 
As for HD, the biggest therapeutic progress was observed in gene-based strategies aimed at directly 76 
reducing the expression of the mutant protein. Of these, the antisense oligonucleotide (ASO) 77 
Tominersen (IONIS-HTTRx) developed by Ionis Pharmaceuticals, showed a dose-dependent ability 78 
to reduce the mutant HD-causing protein in 34 HD patients participating in randomized, double-79 
blind, multiple-ascending-dose Phase 1–2a trial [10]. In spring of 2020, Roche announced that it had 80 
completed its enrolment of 791 HD patients for a Phase 3 multi-centered trial of Tominersen 81 
(ClinicalTrials.gov Identifier: NCT03761849), aimed at evaluating the safety and efficacy of the ASO 82 
over a 2-year period.   83 
 84 
Conversely, therapeutic development for PD has seen less progress towards novel treatments that 85 
could potentially replace levodopa, which has well-described acute and chronic adverse effects [11]. 86 
However, in late summer of 2019, the FDA approved istradefylline, developed by Kyowa Kirin, as a 87 
complementary PD drug that can be used when symptoms appear between regular levodopa doses 88 
[12].  89 
 90 
There have thus been positive therapeutic advancements in the field of neurodegenerative diseases 91 
since Hussain et al. published their review approximately 2 years ago [4]. Not to be forgotten or 92 
dismissed are also the countless research and medical endeavors that have contributed to the 93 
culmination of these accomplishments, including the numerous experiments with negative outcomes 94 
that have paved the way for evolving knowledge, new insights and changing paradigms. 95 
 96 
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At the end of their review, Hussain et al. stated: “Therefore, despite substantial advances in the 98 
development of symptomatic treatments for neurodegenerative diseases, scientific efforts should not 99 
waiver, and perseverance is called for to attain this global goal” [4]. This ultimate goal being to 100 
significantly delay, if not prevent, disease progression and early death in patients with AD, PD, HD 101 
and other devastating neurodegenerative diseases. It is thus imperative that, amidst the recent 102 
positive therapeutic developments, scientific, clinical and pharmaceutical endeavors continue to 103 
pursue strategies such as improving delivery of ASOs with chemical modifications, bioconjugations 104 
and nanocarriers [13], repurposing drugs used in other conditions that target shared aberrant 105 
pathways [14,15] and considering the impact and therapeutic importance of non-neuronal tissues and 106 
organs [16–18].  107 
 108 
Combining current effective approaches with additional relevant strategies that have proven 109 
beneficial in other conditions will most likely be the key to successfully achieving the goal of 110 
providing life-saving treatments to patients living with neurodegenerative diseases.   111 
 112 
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